Rocket Pharmaceuticals, Inc. (RCKT)
RCKT Stock Price Chart
Explore Rocket Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze RCKT price movements and trends.
RCKT Company Profile
Discover essential business fundamentals and corporate details for Rocket Pharmaceuticals, Inc. (RCKT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
18 Feb 2015
Employees
299.00
Website
https://rocketpharma.comCEO
Gaurav D. Shah
Description
Rocket Pharmaceuticals, Inc., operating alongside its affiliates, is an innovative biotechnology enterprise dedicated to pioneering gene therapies for rare and severely debilitating diseases. The company's active clinical pipeline features multiple promising programs. It is currently progressing three ex vivo lentiviral vector therapies aimed at specific genetic conditions: Fanconi anemia, characterized by a bone marrow defect that hinders blood cell production; leukocyte adhesion deficiency-I, an inherited disorder resulting in a compromised immune system; and pyruvate kinase deficiency, a rare autosomal recessive red blood cell ailment leading to chronic non-spherocytic hemolytic anemia. Complementing these, Rocket Pharmaceuticals also has an in vivo adeno-associated virus program underway for Danon disease, a serious multi-organ lysosomal storage disorder that tragically often results in early mortality due to heart failure. To facilitate its extensive research and development efforts, the company has established key licensing partnerships with esteemed institutions such as the Fred Hutchinson Cancer Research Center, European research bodies including CIEMAT and its collaborators (Centro de Investigacion Biomedica En Red and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz), UCL Business PLC (in conjunction with CIEMAT), The Regents of the University of California, and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. maintains its primary corporate location in Cranbury, New Jersey.
RCKT Financial Timeline
Browse a chronological timeline of Rocket Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is $1.02, while revenue estimate is $222.22k.
Earnings released on 7 May 2026
EPS came in at -$0.42 falling short of the estimated -$0.41 by -2.44%.
Earnings released on 26 Feb 2026
EPS came in at -$0.38 surpassing the estimated -$0.42 by +9.52%.
Earnings released on 6 Nov 2025
EPS came in at -$0.45 surpassing the estimated -$0.48 by +6.25%.
Earnings released on 7 Aug 2025
EPS came in at -$0.59 falling short of the estimated -$0.57 by -3.51%.
Earnings released on 8 May 2025
EPS came in at -$0.56 surpassing the estimated -$0.59 by +5.08%.
Earnings released on 27 Feb 2025
EPS came in at -$0.62 surpassing the estimated -$0.68 by +8.82%.
Earnings released on 7 Nov 2024
EPS came in at -$0.71 surpassing the estimated -$0.78 by +8.97%.
Earnings released on 5 Aug 2024
EPS came in at -$0.74 matching the estimated -$0.74.
Earnings released on 6 May 2024
EPS came in at -$0.66 surpassing the estimated -$0.69 by +4.35%.
Earnings released on 26 Feb 2024
EPS came in at -$0.64 surpassing the estimated -$0.80 by +20.00%, while revenue for the quarter reached $10.31m .
Earnings released on 6 Nov 2023
EPS came in at -$0.75 surpassing the estimated -$0.82 by +8.54%.
Earnings released on 10 Aug 2023
EPS came in at -$0.82 falling short of the estimated -$0.80 by -2.50%.
Earnings released on 4 May 2023
EPS came in at -$0.73 surpassing the estimated -$0.86 by +15.12%.
Earnings released on 27 Feb 2023
EPS came in at -$0.92 falling short of the estimated -$0.81 by -13.58%.
Earnings released on 3 Nov 2022
EPS came in at -$0.87 falling short of the estimated -$0.77 by -12.99%.
Earnings released on 8 Aug 2022
EPS came in at -$0.83 falling short of the estimated -$0.68 by -22.06%.
Earnings released on 5 May 2022
EPS came in at -$0.67 surpassing the estimated -$0.70 by +4.29%.
Earnings released on 24 Feb 2022
EPS came in at -$0.69 surpassing the estimated -$0.75 by +8.00%.
Earnings released on 3 Nov 2021
EPS came in at -$0.79 falling short of the estimated -$0.58 by -36.21%.
Earnings released on 9 Aug 2021
EPS came in at -$0.55 surpassing the estimated -$0.66 by +16.67%.
RCKT Stock Performance
Access detailed RCKT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
